

NCT02502734 Raw comparison:

Summary:
CHIA has 29 criteria while your personal folder has 31 criteria
Total found criteria: 29/29
Total not Found: 0/29
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Aged 5 years to less than 12 years at Visit 1 At   │ Aged 5 years to less than 12 years at Visit 1 At   │
│ least 15 (25%) children of the total study         │ least 15 (25%) children of the total study         │
│ population must be aged 5 to less than 8 years     │ population must be aged 5 to less than 8 years     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male or pre-menarchial female subjects             │ Male or pre-menarchial female subjects             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects must be pre-adolescent without any signs  │ Subjects must be pre-adolescent without any signs  │
│ of puberty (Tanner Stage 1)                        │ of puberty (Tanner Stage 1)                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Normal range for their height and weight Weight    │ Normal range for their height and weight Weight    │
│ and height measurements should fall within the     │ and height measurements should fall within the     │
│ percentile range 3-97% of normal values for age    │ percentile range 3-97% of normal values for age    │
│ according to Danish growth charts                  │ according to Danish growth charts                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have a documented diagnosis of persistent asthma   │ Have a documented diagnosis of persistent asthma   │
│ as defined by the National Institutes of Health    │ as defined by the National Institutes of Health    │
│ for at least 3 months prior to the Screening Visit │ for at least 3 months prior to the Screening Visit │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A pre-bronchodilatory forced expiratory flow in 1  │ A pre-bronchodilatory forced expiratory flow in 1  │
│ second (FEV1) at Visit 1 (Screening) >=80%         │ second (FEV1) at Visit 1 (Screening) \>=80%        │
│ predicted There should be no Short acting beta-    │ predicted There should be no Short acting beta-    │
│ agonist (SABA) use within 4 hours of this          │ agonist (SABA) use within 4 hours of this          │
│ measurement                                        │ measurement                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Using one of the following asthma therapies prior  │ Using one of the following asthma therapies prior  │
│ to entry into the study SABA inhaler alone (e g    │ to entry into the study SABA inhaler alone (e g    │
│ salbutamol) on an as required basis and/or Regular │ salbutamol) on an as required basis and/or Regular │
│ non-inhaled corticosteroid (ICS) controller        │ non-inhaled corticosteroid (ICS) controller        │
│ medications for asthma (e g cromones or            │ medications for asthma (e g cromones or            │
│ leukotriene receptor antagonists) and/or           │ leukotriene receptor antagonists) and/or           │
│ Previously treated with ICS (equipotent to inhaled │ Previously treated with ICS (equipotent to inhaled │
│ budesonide <=400 micrograms (mcg) total daily      │ budesonide \<=400 micrograms (mcg) total daily     │
│ dose) There must be no ICS use within 2 weeks of   │ dose) There must be no ICS use within 2 weeks of   │
│ Visit 1 (Screening)                                │ Visit 1 (Screening)                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to replace their current SABA treatment with  │ Able to replace their current SABA treatment with  │
│ study supplied rescue SABA provided at Visit 1 for │ study supplied rescue SABA provided at Visit 1 for │
│ use as needed for the duration of the study        │ use as needed for the duration of the study        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Written informed consent from at least one         │ Written informed consent from at least one         │
│ parent/care giver (legal guardian) and             │ parent/care giver (legal guardian) and             │
│ accompanying informed assent from the subject      │ accompanying informed assent from the subject      │
│ (where the subject is able to provide assent)      │ (where the subject is able to provide assent)      │
│ prior to admission to the study (1) If applicable  │ prior to admission to the study (1) If applicable  │
│ subject must be able and willing to give assent to │ subject must be able and willing to give assent to │
│ take part in the study according to the local      │ take part in the study according to the local      │
│ requirement The study investigator is accountable  │ requirement The study investigator is accountable  │
│ for determining a child's capacity to assent to    │ for determining a child's capacity to assent to    │
│ participation in a research study taking into      │ participation in a research study taking into      │
│ consideration any standards set by the responsible │ consideration any standards set by the responsible │
│ independent ethics committee (IEC) (2) Subject and │ independent ethics committee (IEC) (2) Subject and │
│ their legal guardian(s) understand that the study  │ their legal guardian(s) understand that the study  │
│ requires them to be treated on an outpatient basis │ requires them to be treated on an outpatient basis │
│ (3) Subject and their legal guardian(s) understand │ (3) Subject and their legal guardian(s) understand │
│ that they must comply with study medication and    │ that they must comply with study medication and    │
│ study assessments including recording of peak      │ study assessments including recording of peak      │
│ expiratory flow and rescue SABA use attending      │ expiratory flow and rescue SABA use attending      │
│ scheduled study visits and being accessible by a   │ scheduled study visits and being accessible by a   │
│ telephone call                                     │ telephone call                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A history of life-threatening asthma defined for   │ A history of life-threatening asthma defined for   │
│ this protocol as an asthma episode that required   │ this protocol as an asthma episode that required   │
│ intubation hypercapnea requiring non-invasive      │ intubation hypercapnea requiring non-invasive      │
│ ventilatory support respiratory arrest hypoxic     │ ventilatory support respiratory arrest hypoxic     │
│ seizures or asthma-related syncopal episode(s)     │ seizures or asthma-related syncopal episode(s)     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with a history of asthma exacerbation     │ Subjects with a history of asthma exacerbation     │
│ requiring the use of systemic corticosteroids      │ requiring the use of systemic corticosteroids      │
│ (tablets suspension or injection) for at least 3   │ (tablets suspension or injection) for at least 3   │
│ days or a depot corticosteroid injection or        │ days or a depot corticosteroid injection or        │
│ emergency room attendance (within 3 months) or     │ emergency room attendance (within 3 months) or     │
│ requiring hospitalization for asthma (within 6     │ requiring hospitalization for asthma (within 6     │
│ months) prior to screening                         │ months) prior to screening                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant non-reversible active pulmonary        │ Significant non-reversible active pulmonary        │
│ disease (e g cystic fibrosis bronchiectasis        │ disease (e g cystic fibrosis bronchiectasis        │
│ tuberculosis)                                      │ tuberculosis)                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Culture-documented or suspected bacterial or viral │ Culture-documented or suspected bacterial or viral │
│ infection of the upper or lower respiratory tract  │ infection of the upper or lower respiratory tract  │
│ sinus or middle ear that is not resolved within 4  │ sinus or middle ear that is not resolved within 4  │
│ weeks of Visit 1 and led to a change in asthma     │ weeks of Visit 1 and led to a change in asthma     │
│ management or in the opinion of the Investigator   │ management or in the opinion of the Investigator   │
│ is expected to affect the subject's asthma status  │ is expected to affect the subject's asthma status  │
│ or the subject's ability to participate in the     │ or the subject's ability to participate in the     │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any fracture in the leg to be measured within 6    │ Any fracture in the leg to be measured within 6    │
│ months prior to the screening visit                │ months prior to the screening visit                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any metabolic disorders or other diseases that may │ Any metabolic disorders or other diseases that may │
│ impact on normal growth patterns                   │ impact on normal growth patterns                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No major surgery requiring general anaesthesia for │ No major surgery requiring general anaesthesia for │
│ at least 3 months prior to the screening visit     │ at least 3 months prior to the screening visit     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No febrile illnesses with temperature >39 degree   │ No febrile illnesses with temperature \>39 degree  │
│ celsius for more than five consecutive days within │ celsius for more than five consecutive days within │
│ the week preceding the Screening Visit             │ the week preceding the Screening Visit             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any significant abnormality or medical condition   │ Any significant abnormality or medical condition   │
│ identified at the screening medical assessment     │ identified at the screening medical assessment     │
│ (including serious psychological disorder) that in │ (including serious psychological disorder) that in │
│ the Investigator's opinion preclude entry into the │ the Investigator's opinion preclude entry into the │
│ study due to risk to the subject or that may       │ study due to risk to the subject or that may       │
│ interfere with the outcome of the study            │ interfere with the outcome of the study            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinical visual evidence of candidiasis at Visit 1 │ Clinical visual evidence of candidiasis at Visit 1 │
│ (Screening)                                        │ (Screening)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any of the prohibited medications listed in │ Use of any of the prohibited medications listed in │
│ protocol                                           │ protocol                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Strenuous physical exercise within 3 hours of      │ Strenuous physical exercise within 3 hours of      │
│ Visit 1 (Screening)                                │ Visit 1 (Screening)                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Drug allergies Any adverse reaction including      │ Drug allergies Any adverse reaction including      │
│ immediate or delayed hypersensitivity to any       │ immediate or delayed hypersensitivity to any       │
│ intranasal inhaled or systemic corticosteroid      │ intranasal inhaled or systemic corticosteroid      │
│ therapy Known or suspected sensitivity to the      │ therapy Known or suspected sensitivity to the      │
│ constituents of the ELLIPTA Inhaler (i e lactose   │ constituents of the ELLIPTA Inhaler (i e lactose   │
│ FF)                                                │ FF)                                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Milk Protein Allergy History of severe milk        │ Milk Protein Allergy History of severe milk        │
│ protein allergy                                    │ protein allergy                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The subject has participated in a clinical trial   │ The subject has participated in a clinical trial   │
│ and has received an investigational product within │ and has received an investigational product within │
│ the following time period prior to the first       │ the following time period prior to the first       │
│ dosing day in the current study 30 days 5 half-    │ dosing day in the current study 30 days 5 half-    │
│ lives or twice the duration of the biological      │ lives or twice the duration of the biological      │
│ effect of the investigational product (whichever   │ effect of the investigational product (whichever   │
│ is longer)                                         │ is longer)                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Exposure to more than 4 investigational medicinal  │ Exposure to more than 4 investigational medicinal  │
│ products within 12 months prior to the first       │ products within 12 months prior to the first       │
│ dosing day                                         │ dosing day                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unable to use the ELLIPTA inhaler and peak flow    │ Unable to use the ELLIPTA inhaler and peak flow    │
│ meter correctly                                    │ meter correctly                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ An affiliation with the Investigator site the      │ An affiliation with the Investigator site the      │
│ parents/guardians or child is an immediate family  │ parents/guardians or child is an immediate family  │
│ member of the participating Investigator sub-      │ member of the participating Investigator sub-      │
│ Investigator study coordinator or employee of the  │ Investigator study coordinator or employee of the  │
│ participating Investigator                         │ participating Investigator                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The Parent or Guardian has a history of            │ The Parent or Guardian has a history of            │
│ psychiatric disease intellectual deficiency        │ psychiatric disease intellectual deficiency        │
│ substance abuse or other condition (e g inability  │ substance abuse or other condition (e g inability  │
│ to read comprehend or write) which may affect      │ to read comprehend or write) which may affect      │
│ validity of consent to participate in the study    │ validity of consent to participate in the study    │
│ adequate supervision of the subject during the     │ adequate supervision of the subject during the     │
│ study compliance of subject with study medication  │ study compliance of subject with study medication  │
│ and study procedures (e g completion of daily      │ and study procedures (e g completion of daily      │
│ diary attending scheduled clinic visits) subject   │ diary attending scheduled clinic visits) subject   │
│ safety and well-being                              │ safety and well-being                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Children in care Children who are wards of the     │ Children in care Children who are wards of the     │
│ government or state are not eligible for           │ government or state are not eligible for           │
│ participation in this study                        │ participation in this study                        │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 5 Years  │
├───────────────────────────────────┤
│ Must have maximum age of 11 Years │
╘═══════════════════════════════════╛